Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease
- PMID: 2979672
- DOI: 10.1111/j.1365-2036.1987.tb00627.x
Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease
Abstract
Gastrointestinal transit of an enteric coated delayed release 5-aminosalicylic acid tablet radiolabelled with 111indium has been monitored in a total of 13 patients with Crohn's disease and ulcerative colitis. More than 70% of the tablets disintegrated in the small intestine, on average 3.2 hours after emptying from the stomach. Dispersed preparation was detected in the proximal colon of all the patients, except one with an ileostomy. Mean peak plasma concentrations of 5-aminosalicylic acid and its metabolite acetyl-5-aminosalicylic acid occurred 3-4 hours after gastric emptying. The tablets provide a reliable means of drug delivery to the ileum and proximal colon.
Similar articles
-
Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.Scand J Gastroenterol Suppl. 1990;172:47-51. doi: 10.3109/00365529009091910. Scand J Gastroenterol Suppl. 1990. PMID: 2353171 Clinical Trial.
-
Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet.Aliment Pharmacol Ther. 1987 Jun;1(3):209-16. doi: 10.1111/j.1365-2036.1987.tb00620.x. Aliment Pharmacol Ther. 1987. PMID: 2979223
-
Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.Aliment Pharmacol Ther. 1990 Oct;4(5):497-505. doi: 10.1111/j.1365-2036.1990.tb00496.x. Aliment Pharmacol Ther. 1990. PMID: 2129637
-
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.Dan Med Bull. 1989 Sep;36(4):378-93. Dan Med Bull. 1989. PMID: 2572403 Review. No abstract available.
-
Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 1991 Oct;5(5):449-70. doi: 10.1111/j.1365-2036.1991.tb00515.x. Aliment Pharmacol Ther. 1991. PMID: 1793778 Review.
Cited by
-
Oroileal transit of slow release 5-aminosalicylic acid.Gut. 1993 May;34(5):669-75. doi: 10.1136/gut.34.5.669. Gut. 1993. PMID: 8504969 Free PMC article.
-
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD000543. doi: 10.1002/14651858.CD000543.pub5. Cochrane Database Syst Rev. 2020. PMID: 32786164 Free PMC article.
-
Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.Drugs. 1989 Jan;37(1):73-86. doi: 10.2165/00003495-198937010-00005. Drugs. 1989. PMID: 2651087 Review.
-
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Aug 28;8:CD000544. doi: 10.1002/14651858.CD000544.pub5. PMID: 27158764 Free PMC article. Updated.
-
Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.AAPS PharmSciTech. 2021 Nov 3;22(8):264. doi: 10.1208/s12249-021-02133-4. AAPS PharmSciTech. 2021. PMID: 34734325 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources